Foster City, CA — June 2, 2026 — Signios Bio, a science-first biotechnology company providing end-to-end multiomics services, today announced the recipients of its Xenium 5K Spatial Transcriptomics Grant Program, launched in collaboration with 10x Genomics. The program was established to support researchers applying high-plex spatial transcriptomics to complex biological questions in human and mouse […]
Foster City, Calif. — Signios Bio today announced the launch of a new grant program supporting innovative spatial transcriptomics research using the 10x Genomics Xenium 5K Spatial Transcriptomics platform. The program is designed to enable U.S.-based researchers to generate high-plex, single-cell-resolution spatial gene expression data in human and mouse tissues. The Signios Bio Xenium 5K
FOSTER CITY, Calif. – Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced the winners of the Illumina–Signios Bio Proteomics Grant Program. The program was established to advance proteogenomic research through access to the Illumina Protein Prep 9.5K™, the industry’s largest NGS-based proteomics panel. Following
In the ever-evolving field of healthcare, the way we understand and treat disease is undergoing a seismic shift. Traditionally, research in biology and medicine has approached complex health challenges from a single layer, focusing either on genetics, proteomics, metabolomics or observable phenotypes. But this siloed view is no longer sufficient. Biology doesn’t operate in isolation;
From the 2024 Nobel Prize for artificial intelligence (AI)-based protein design to the rollout of a new AI tool at the FDA to accelerate reviews and other agency processes, AI has become a key player in drug discovery and development. In context of the recent oncology-focused research meetings — the 2025 Annual Meeting of the
FOSTER CITY, Calif.–(BUSINESS WIRE)–Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate
FOSTER CITY, California, APRIL 10, 2025 — Signios Biosciences (“Signios Bio”), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc. This milestone marks a new era, better positioning the brand in the US on its
